Reviewing CytRx Corporation (CYTR)’s and Translate Bio Inc. (NASDAQ:TBIO)’s results

As Biotechnology companies, CytRx Corporation (OTCMKTS:CYTR) and Translate Bio Inc. (NASDAQ:TBIO) are our subject to contrast. And more specifically their profitability, analyst recommendations, risk, institutional ownership, dividends, earnings and valuation.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
CytRx Corporation N/A 45.73 N/A -0.31 0.00
Translate Bio Inc. 10 132.67 N/A -2.44 0.00

Table 1 shows the gross revenue, earnings per share (EPS) and valuation for CytRx Corporation and Translate Bio Inc.

Profitability

Table 2 provides the net margins, return on assets and return on equity of the two firms.

Net Margins Return on Equity Return on Assets
CytRx Corporation 0.00% 0% 0%
Translate Bio Inc. 0.00% 0% 0%

Analyst Recommendations

The next table highlights the delivered recommendations and ratings for CytRx Corporation and Translate Bio Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
CytRx Corporation 0 0 0 0.00
Translate Bio Inc. 0 0 1 3.00

Competitively the average price target of Translate Bio Inc. is $21, which is potential 98.49% upside.

Institutional & Insider Ownership

CytRx Corporation and Translate Bio Inc. has shares held by institutional investors as follows: 10.22% and 58.3%. 8.5% are CytRx Corporation’s share held by insiders. On the other hand, insiders held about 31.15% of Translate Bio Inc.’s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
CytRx Corporation 1.14% 4.41% -34.85% -35.8% -69.25% -20.9%
Translate Bio Inc. -9.89% -33.66% -14.41% 41.7% -34.32% 6.93%

For the past year CytRx Corporation had bearish trend while Translate Bio Inc. had bullish trend.

Summary

On 5 of the 6 factors Translate Bio Inc. beats CytRx Corporation.

CytRx Corporation operates as a biopharmaceutical research and development company specializing in oncology. The companyÂ’s product candidate is the aldoxorubicin, which is in Phase III clinical trial as a therapy for patients with soft tissue sarcomas (STS) whose tumors have progressed following treatment with chemotherapy; in Phase IIb clinical trial in small cell lung cancer; in Phase II clinical trial in HIV-related Kaposi's sarcoma; in Phase II clinical trial in patients with late-stage glioblastoma (brain cancer); in Phase Ib trial in combination with ifosfamide in patients with STS; and in Phase Ib trial in combination with gemcitabine in subjects with metastatic solid tumors. It also has completed Phase IIb and Phase Ib/II clinical trials with aldoxorubicin as a first-line therapy for STS; a Phase Ib clinical trial of aldoxorubicin in combination with doxorubicin in patients with advanced solid tumors; and a Phase Ib pharmacokinetics clinical trial in patients with metastatic solid tumors. The company is also developing anti-cancer drug conjugates, which utilizes its Linker Activated Drug Release technology. CytRx Corporation was founded in 1985 and is headquartered in Los Angeles, California.

Translate Bio, Inc., a messenger RNA therapeutics company, engages in developing medicines to treat diseases caused by protein or gene dysfunction. It is developing MRT5005 that is in Phase I/II clinical trial for the treatment of cystic fibrosis; and MRT5201 for the treatment of ornithine transcarbamylase deficiency. It has strategic alliances with Sanofi Pasteur. The company was formerly known as RaNA Therapeutics, Inc. and changed its name to Translate Bio, Inc. in June 2017. Translate Bio, Inc. was founded in 2011 and is headquartered in Lexington, Massachusetts.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.